title: CHOP chemotherapy for the treatment of canine multicentric T-cell lymphoma.
abstract: Dogs with multicentric T-cell lymphoma are commonly treated with CHOP chemotherapy protocols that include cyclophosphamide, doxorubicin, vincristine and prednisone. The purpose of this study was to evaluate the use of CHOP chemotherapy for dogs with multicentric T-cell lymphoma. Identification of prognostic factors in this specific subset of dogs was of secondary interest. Twenty-three out of 24 dogs responded to CHOP chemotherapy and these dogs remained on the protocol for a median of 146 days. No variable was associated with progression free survival (PFS) including stage, substage, hypercalcemia or radiographic evidence of a cranial mediastinal mass. The median overall survival time (OST) for all dogs was 235 days. Dogs that were thrombocytopenic at presentation experienced a significantly longer OST (323 versus 212 days, P=0.01).
authors.affiliation: Department of Surgical and Radiological Sciences, One Shields Avenue, University of California, Davis, CA 95616, USA. rbrebhun@ucdavis.edu
authors.forename: R B
authors.initials: RB
authors.lastname: Rebhun
authors.forename: M S
authors.initials: MS
authors.lastname: Kent
authors.forename: S A E B
authors.initials: SA
authors.lastname: Borrofka
authors.forename: S
authors.initials: S
authors.lastname: Frazier
authors.forename: K
authors.initials: K
authors.lastname: Skorupski
authors.forename: C O
authors.initials: CO
authors.lastname: Rodriguez
mesh_terms: D000818:Animals; D000970:Antineoplastic Agents / Q000627:therapeutic use*; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000008:administration & dosage / Q000627:therapeutic use*; D002140:California; D003520:Cyclophosphamide / Q000008:administration & dosage / Q000627:therapeutic use; D018572:Disease-Free Survival; D004283:Dog Diseases / Q000188:drug therapy*; D004285:Dogs; D004317:Doxorubicin / Q000008:administration & dosage / Q000627:therapeutic use; D005260:Female; D016399:Lymphoma, T-Cell / Q000188:drug therapy / Q000662:veterinary*; D008297:Male; D009367:Neoplasm Staging; D011241:Prednisone / Q000008:administration & dosage / Q000627:therapeutic use; D011379:Prognosis; D012189:Retrospective Studies; D014750:Vincristine / Q000008:administration & dosage / Q000627:therapeutic use
chemical_list: D000970:Antineoplastic Agents; D014750:Vincristine; D004317:Doxorubicin; D003520:Cyclophosphamide; D011241:Prednisone